TAKEDA PHARMACEUTICAL Reports JPY 119.1 Billion in Total Revenue for Fiscal Year 2023 Q3.

March 19, 2023

Earnings Overview

For the fiscal year 2023 third quarter, TAKEDA PHARMACEUTICAL ($LTS:0RN3) reported total revenue of JPY 119.1 billion, a 106.2% increase from the same quarter of the year before. Net income also saw a 21.7% rise to JPY 1096.5 billion.

Market Price

The stock opened at €41.3 and closed at the same price. The strong results were driven by the company’s expanding portfolio of innovative products, including their newly approved cancer treatments, as well as their commitment to developing new drugs to treat rare diseases. TAKEDA PHARMACEUTICAL has also committed to investing more resources into R&D, as well as expanding their global footprint and presence in emerging markets. The company’s stock responded positively to the news, with investors showing strong confidence in TAKEDA PHARMACEUTICAL’s ability to deliver consistent, strong results.

Going forward, the company is looking to continue to drive growth through strategic investments, partnerships, and venturing into new markets. With an expanding portfolio of products and an increasingly global presence, TAKEDA PHARMACEUTICAL is well positioned to continue delivering strong results for its shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Takeda Pharmaceutical. More…

    Total Revenues Net Income Net Margin
    3.94M 274.52k 8.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Takeda Pharmaceutical. More…

    Operations Investing Financing
    1.06M -194.25k -946.35k
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Takeda Pharmaceutical. More…

    Total Assets Total Liabilities Book Value Per Share
    13.5M 7.33M 3.97k
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Takeda Pharmaceutical are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    6.8% 130.7% 9.6%
    FCF Margin ROE ROA
    20.7% 3.7% 1.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale provides an analysis of the fundamentals of TAKEDA PHARMACEUTICAL, a pharmaceutical company headquartered in Tokyo, Japan. After analyzing the company’s financial and business aspects, GoodWhale has assessed TAKEDA PHARMACEUTICAL as a medium risk investment. Our analysis has detected 2 risk warnings in TAKEDA PHARMACEUTICAL’s income sheet and balance sheet. To access this warning and other useful information, become a registered user on GoodWhale. We can help you make informed decisions about your investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    TAKEDA PHARMACEUTICAL has reported a strong financial performance in its fiscal year 2023 third quarter. Total revenue increased by 106.2%, reaching JPY 119.1 billion, while net income increased 21.7% to JPY 1096.5 billion. This significant growth in such a short period of time is a positive sign for investors, indicating that the company is on track to reach its goals.

    The increase in revenue and profits indicates that the company’s strategies are proving successful and its products are gaining popularity. The company’s future looks promising and investors should consider adding TAKEDA PHARMACEUTICAL to their portfolio.

    Recent Posts

    Leave a Comment